Target intelligence / Profile preview

G protein subunit alpha L (GαL)

Target
GαL
Molecular classification
Guanine nucleotide-binding protein (G protein) alpha subunit, Signal transduction protein, Heterotrimeric G protein component
01

Overview

"G protein subunit alpha L" is not a standard, widely recognized name for any human G protein alpha subunit. Heterotrimeric G proteins consist of alpha, beta, and gamma subunits, with the alpha subunit playing a central role in GDP/GTP binding and hydrolysis and determining G protein class and signaling specificity. Major alpha subunit subfamilies include Gαs, Gαi/o, Gαq/11, and Gα12/13, each encoded by distinct genes. The subclass "L" does not match these canonical classifications, and no major databases or reviews identify a "G protein subunit alpha L" as a separate entity. This suggests the term is either a misnomer, transcription/translation error, or an extremely rare/obsolete alias for another alpha subunit, potentially GNAI3 (Gαi3), although this is not definitive. Therefore, "G protein subunit alpha L" should be considered ambiguous or incorrect for structured biomedical curation.

Other names
GαL (rare/ambiguous)G protein alpha subunit L (rare/ambiguous)Possible confusion with GNAI3 (G protein subunit alpha i3, also known as Gαi3)
02

Mechanism of action

For drugs/toxins that affect G proteins: typically modulation of GDP/GTP binding, inhibition or activation of downstream effectors, or disruption of Gα subunit interactions

03

Biological functions

Signal transductionRegulates intracellular signaling cascades in response to GPCR activationModulates activity of effector enzymes such as adenylyl cyclase, phospholipase C, and ion channels
04

Disease associations

Cancer (for G protein signaling in general)Neurological diseases (for G protein signaling in general)Cardiovascular disease (for G protein signaling in general)Other (varies with specific alpha subunit, but “alpha L” is not directly associated with specific diseases)
05

Safety considerations

Targeting G proteins systemically can cause broad adverse effects, given their central role in cell signaling and multiple organ systemsNo specific safety data for "G protein subunit alpha L"
06

Interacting drugs

No drugs known to specifically target a "G protein subunit alpha L"

2 more in the full profile.

07

Biomarkers

No well-validated biomarkers for "alpha L" as a distinct subunitG protein subunit isoforms may be investigated as biomarkers in research contexts, depending on disease and tissue

Beyond the preview

Go deeper on G protein subunit alpha L (GαL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G protein subunit alpha L (GαL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call